Literature DB >> 31112346

Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations.

Christopher B Anderson1, Michael Lipsky1, Subhadra V Nandula2, Christopher E Freeman3, Thomas Matthews3, Caitlin E Walsh3, Gen Li4, Matthias Szabolcs3, Mahesh M Mansukhani3, James M McKiernan1, Vundavalli V Murty3.   

Abstract

The cytogenetic alterations in renal oncocytoma (RO) are poorly understood. We analyzed 130 consecutive RO for karyotypic alterations. Clonal chromosome abnormalities were identified in 63 (49%) cases, which could be categorized into three classes of mutually exclusive cytogenetic categories. Class 1 (N = 20) RO had diploid karyotypes with characteristic 11q13 rearrangement in balanced translocations with 10 or more different chromosome partners in all cases. We identified recurrent translocation partners at 5q35, 6p21, 9p24, 11p13-14, and 11q23, and confirmed that CCND1 gene rearrangement at 11q13 utilizing fluorescence in situ hybridization (FISH). Class 2 RO (N = 25) exhibited hypodiploid karyotypes with loss of chromosome 1 and/or losses of Y in males and X in females in all cases. The class 3 tumors comprising of 18 cases showed diverse types of abnormalities with the involvement of two or more chromosomes exclusive of abnormalities seen in classes 1 and 2 tumors. Furthermore, karyotypically uninformative cases were subjected to FISH analysis to identify classes 1 and 2 abnormalities. In this group, we found similar frequencies of CCND1 rearrangement, loss of chromosome 1 or Y as with karyotypically abnormal cases. We validated our results against 91 tumors from the Mitelman database. Correlation of clinical data with all the three classes of ROs showed no clear evidence of overall patient survival. Our findings support the hypothesis that RO exhibit three principal cytogenetic categories, which may have different roles in initiation and/or progression. These cytogenetic markers provide a key tool in the diagnostic evaluation of RO.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  11q13 rearrangement; cyclin D1; cytogenetics; loss of chromosome 1; renal oncocytoma

Year:  2019        PMID: 31112346     DOI: 10.1002/gcc.22766

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  4 in total

Review 1.  Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss.

Authors:  Payal Kapur; Ming Gao; Hua Zhong; Dinesh Rakheja; Qi Cai; Ivan Pedrosa; Vitaly Margulis; Lin Xu; Lisa Kinch; James Brugarolas
Journal:  Adv Anat Pathol       Date:  2021-07-01       Impact factor: 4.571

Review 2.  [Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference].

Authors:  Oliver Hommerding; Yves Allory; Pedram Argani; Tarek A Bismar; Lukas Bubendorf; Sofía Canete-Portillo; Alcides Chaux; Ying-Bei Chen; Liang Cheng; Antonio L Cubilla; Lars Egevad; Anthony J Gill; David J Grignon; Arndt Hartmann; Ondrej Hes; Muhammad T Idrees; Chia-Sui Kao; Margaret A Knowles; Leendert H J Looijenga; Tamara L Lotan; Colin C Pritchard; Mark A Rubin; Scott A Tomlins; Theodorus H Van der Kwast; Elsa F Velazquez; Joshua I Warrick; Sean R Williamson; Glen Kristiansen
Journal:  Pathologe       Date:  2021-01-04       Impact factor: 1.011

Review 3.  TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background.

Authors:  Kristyna Pivovarcikova; Reza Alaghehbandan; Tomas Vanecek; Riuko Ohashi; Tomas Pitra; Ondrej Hes
Journal:  Biomedicines       Date:  2022-01-29

Review 4.  Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach.

Authors:  Reza Alaghehbandan; Delia Perez Montiel; Ana Silvia Luis; Ondrej Hes
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.